Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.71 |
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.71 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.71 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.71 |
| ▸ | PDE4A | P27815 | 1/20 | 0.71 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.71 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | PPARG | P37231 | 4/20 | 0.36 |
| ▸ | THRB | P10828 | 3/20 | 0.36 |
| ▸ | TTR | P02766 | 2/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25478285 | 0.84 | TDP1 (0.72) | TDP1CYP2C9LMNACYP1A2HIF1A | |
| Iopanoic Acid SCHEMBL38976 | 0.83 | LMNA (1.00) | TDP1CYP2C9LMNACYP1A2HIF1A | |
| Iopanoic Acid SCHEMBL29358912 | 0.83 | LMNA (1.00) | TDP1CYP2C9LMNACYP1A2HIF1A | |
| SCHEMBL19379584 | 0.82 | TDP1 (0.69) | TDP1CYP2C9LMNACYP1A2HIF1A | |
| SCHEMBL10495750 | 0.81 | CYP1A2 (0.70) | TDP1CYP2C9LMNACYP1A2HIF1A | |
| SCHEMBL19678558 | 0.80 | TDP1 (0.67) | TDP1CYP2C9LMNACYP1A2HIF1A | |
| SCHEMBL22097447 | 0.80 | TDP1 (0.67) | TDP1CYP2C9LMNACYP1A2HIF1A | |
| SCHEMBL3866615 | 0.80 | TDP1 (0.67) | TDP1CYP2C9LMNACYP1A2HIF1A | |
| SCHEMBL11373524 | 0.80 | TDP1 (0.66) | TDP1CYP2C9LMNACYP1A2HIF1A | |
| SCHEMBL19260214 | 0.79 | TDP1 (0.64) | TDP1CYP2C9LMNACYP1A2HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 411 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124313-A1 | SITE-SPECIFIC COVALENT LIGATION OF HUMAN SERUM ALBUMIN | UNIV CALIFORNIA (US) | 2026-05-07 | — | — | US | claimed |
| EP-4656211-A2 | COMPOSITIONS FOR EMBOLIZATION | Iberhospitex, S.A. (ES) | 2025-12-03 | — | — | EP | claimed |
| EP-4376905-B1 | COMPOSITIONS FOR EMBOLIZATION | IBERHOSPITEX SA (ES) | 2025-10-22 | — | — | EP | claimed |
| US-20240358885-A1 | COMPOSITIONS FOR EMBOLIZATION | IBERHOSPITEX, S.A. (ES) | 2024-10-31 | — | — | US | claimed |
| EP-4376905-A1 | COMPOSITIONS FOR EMBOLIZATION | Iberhospitex, S.A. (ES) | 2024-06-05 | — | — | EP | claimed |
| WO-2024077212-A2 | SITE-SPECIFIC COVALENT LIGATION OF HUMAN SERUM ALBUMIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-04-11 | — | — | WO | claimed |
| WO-2023006679-A1 | COMPOSITIONS FOR EMBOLIZATION | IBERHOSPITEX, S.A. (ES) | 2023-02-02 | — | — | WO | claimed |
| US-20220313171-A1 | Imaging and Treatment Methods for Early Detection of Diseases | ALGBURI ISHTAR FAISAL (CA) | 2022-10-06 | — | — | US | claimed |
| US-20210069352-A1 | IODINE-BASED PARTICLES | NANOPROBES, INC. | 2021-03-11 | — | — | US | claimed |
| CN-109916691-A | Reagent for cellular esterases dyeing | 迈克生物股份有限公司 | 2019-06-21 | — | — | CN | claimed |
| US-6281515-B1 | Lightweight radiation protective garments | MERIDIAN RESEARCH AND DEVELOPMENT | 2001-08-28 | — | — | US | claimed |
| WO-2000034957-A1 | LIGHTWEIGHT RADIATION PROTECTIVE GARMENTS | MERIDIAN RESEARCH AND DEVELOPMENT (US) | 2000-06-15 | — | — | WO | claimed |
| CN-1179081-A | Osmolyte regulator | TALL HOLDINGS PTY LTD AB (AU) | 1998-04-15 | — | — | CN | claimed |
| CN-1034216-C | 7-(substituted)-9-[(substituted glycyl) amido]-6-demethyl-6-deoxytetracyclines | AMERICAN CYANAMID CO (US) | 1997-03-12 | — | — | CN | claimed |
| CN-1033971-C | 9-[(substituted glycyl) amido]-6-demethyl-6-deoxytetracyclines | AMERICAN CYANAMID CO (US) | 1997-02-05 | — | — | CN | claimed |
| CN-1033087-C | Novel 7-(substituted)-8-(substituted-9-[(substituted glycyl) amido]-6-demethyl-6-deoxytetracyclines | AMERICAN CYANAMID CO (US) | 1996-10-23 | — | — | CN | claimed |
| CN-1087899-A | The 9-[(substituted glycyl) amido)]-6-demethyl-6-deoxidation tsiklomitsin | AMERICAN CYANAMID CO (US) | 1994-06-15 | — | — | CN | claimed |
| CN-1087626-A | The glycyl that novel 7-(replacement)-8-(replacement)-9-[(replaces) amido]-6-demethyl-6-deoxidation tsiklomitsin | AMERICAN CYANAMID CO (US) | 1994-06-08 | — | — | CN | claimed |
| CN-1083805-A | 7-(replacement)-9-[(substituted glycyl) amido]-6-demethylation-6-deoxytetra cycline | AMERICAN CYANAMID CO (US) | 1994-03-16 | — | — | CN | claimed |
| US-4192859-A | MEDICAL DIAGNOSIS USING X-RAYS | E. R. SQUIBB & SONS, INC. (US) | 1980-03-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124313-A1 | SITE-SPECIFIC COVALENT LIGATION OF HUMAN SERUM ALBUMIN | GLP1R, ALB, GIPR | TDP1 2366/4885CYP2C9 3499/4885LMNA 1893/4885 |
| US-20210069352-A1 | IODINE-BASED PARTICLES | TPO, BRI3BP, INSRR | TDP1 3189/4885CYP2C9 4171/4885LMNA 3921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.